Clinical Trials

ACCESS TO THE LATEST

TREATMENTS

Oregon Urology Institute is committed to advancing the standard of care in treating urological disorders and cancers. To achieve this, we are deeply involved in clinical research, giving you access to experimental procedures and treatments that wouldn’t otherwise be available.

If you’d like to join one of our clinical trials, your doctor can help determine if you’re a candidate. Qualified candidates will be informed about potential risks and benefits. Our clinical trial participants are carefully monitored, and you can opt out at any time.

Currently

Enrolling

Here are trials we're currently conducting. Ask your doctor for more information if you're interested in participating.

Prostate Cancer- APA RP
Study Type: Interventional (Clinical Trial)

Study Design:

  • Estimated Enrollment: 94 participants
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Official Title: A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- Colli-Pee
Prospective Collection of Urine Samples from Men Undergoing Prostate Biopsy
Prostate Cancer- DAROL
Study Type: Observational

Study Design:

  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Estimated Enrollment: 1000 participants

Official Title:Darolutamide Observational Study in Non-metastatic Castration-resistant
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- ESCALATE
Study Type:
Interventional

Study Design:

    Interventional Model: Sequential Assignment
  • Intervention Model Description: Lead-in open-label androgen-receptor blocker (ARB) followed by double-blind Radium-223 or placebo.
  • Estimated Enrollment: 499 participants
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Treatment
  • Official Title:
    ESCALATE, A Phase III Randomized Study Comparing Enzalutamide or Darolutamide With Radium-223 vs Enzalutamide or Darolutamide With Placebo and the Effect Upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients
    For more information on this study, visit clinicaltrials.gov

Prostate Cancer- LAEKNA
Study Type: Interventional (Clinical Trial)

Study Design:

  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Allocation: Randomized
  • Intervention Model: Sequential Assignment
  • Intervention Model Description: Phase 1 Dose Escalation to determine Recommended Phase II Dose (RP2D) of LAE001/Prednisone plus Afuresertib in m-CRPC patients. Once RP2D is determined, Phase II will evaluate LAE001/Prednisone plus Afuresertib vs Afuresertib monotherapy in m-CRPC patients.
  • Estimated Enrollment: 74 participants
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Official Title: A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- Lancelot
Official Title: Analyses of Plasma Samples from Patients with Metastatic Prostate Cancer to Support Analytical Validation of a Novel Liquid Based Companion in vitro Diagnostic Test
Prostate Cancer- MAGNITUDE
Study Type: Interventional (Clinical Trial) Study Design:
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
    • Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
For more information on this study, visit clinicaltrials.gov
Prostate Cancer- PREVALENCE
Study Type: Observational

Study Design:

  • Estimated Enrollment: 10000 participants
  • Observational Model: Cohort
  • Time Perspective: Prospective

Official Title: Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- Tak-Rad
Study Type:
Interventional

Study Design:

  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title: A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- TALAPRO-2
Study Type:
Interventional

Study Design:

  • Interventional Model: Parallel Assignment
  • Intervention Model Description: To assess radiographic PFS in men with mCRPC (with no systemic treatments initiated after documentation of mCRCP) treated with talazoparib and enzalutamide vs. placebo plus enzalutamide
  • Estimated Enrollment: 1037 participants
  • Masking: Double-blind
  • Primary Purpose: Treatment
  • Official Title:
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
    For more information on this study, visit clinicaltrials.gov

Ongoing Studies

Not enrolling

Prostate Cancer- Atlas
Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Actual Enrollment: 1503 Participants
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Investigator)
  • Primary Purpose: Treatment

Official Title: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy.
For more information on this study, visit clinicaltrials.gov

Bladder or Renal cancer- AURORA
Study Objective: This study is designed to provide whole blood samples that will be used to assess 5-hydroxmethylated cytosine molecular signatures in cell-free DNA derived from patients that are highly suspected of having with a variety of Cancerous conditions. Subjects are selected for blood donation prior to surgical resection and treatment.
Prostate Cancer- EMBARK
Study Type: Interventional

Study Design:

  • Actual Enrollment: 1068 participants
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy)
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- ProVent
Study Type:

Interventional

Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be randomized 2:1 to the sipuleucel-T arm or the control arm.Subjects randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals. Subjects randomized to the control arm will be followed on AS as standard of care described in the schedule of events.
Masking: None (Open Label)
Primary Purpose: Basic Science

Official Title:
A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer
For more information on this study, visit clinicaltrials.gov

Urethral Stricture- Robust III
Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment Official Title: ROBUST III - Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease - A Randomized Control Trial
For more information on this study, visit clinicaltrials.gov
Prostate Cancer- SAFELY
Study Type: Observational Study Design:
  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Estimated Enrollment: 600 participants
  • Target Follow-Up Duration: 10 Years
  • Official Title: A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.

For more information on this study, visit clinicaltrials.gov
Prostate Cancer- Ulysses

Study Type:
Interventional

Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title:
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
For more information on this study, visit clinicaltrials.gov